Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Multiple myeloma patients get continued access to promising drug

NCT ID NCT02719613

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued treatment with elotuzumab (plus dexamethasone) to 67 multiple myeloma patients who were already benefiting from it in earlier trials. The main goal is to keep providing the drug and track how long patients stay on treatment. Researchers will also monitor any new or serious side effects. This is not a test of whether the drug works, but a way to ensure ongoing access for those who need it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Elotuzumab (with dexamethasone)
What this could lead to
If successful, this study allows patients to keep receiving a treatment that may help control their multiple myeloma without interruption.
What could go wrong
This is an extension study, not a new test of effectiveness. It only includes patients already benefiting, so results may not apply to everyone. Side effects from long-term use remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

67 people

The number who actually took part.

Started

Jul 2016

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol * Receiving elotuzumab and/or other study drugs at the time of signature of informed consent * Males and Females, ages 18 and older Exclusion Criteria: * All participants previously discontinued from an elotuzumab study for any reason * Participants not receiving clinical benefit from previous study therapy * Participants who are not medically well enough to receive study therapy as determined by the investigator Other protocol defined inclusion/exclusion criteria could apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Local Institution - 0001

    Bethlehem, Pennsylvania, 18015, United States

  • Local Institution - 0002

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0003

    Indianapolis, Indiana, 46260, United States

  • Local Institution - 0004

    New York, New York, 10029, United States

  • Local Institution - 0008

    St Louis, Missouri, 63110, United States

  • Local Institution - 0009

    Atlanta, Georgia, 30322, United States

  • Local Institution - 0010

    Halifax, B3H 2Y9, Canada

  • Local Institution - 0011

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0012

    Florence, 50134, Italy

  • Local Institution - 0013

    Genova, 16132, Italy

  • Local Institution - 0014

    Torino, 10126, Italy

  • Local Institution - 0015

    Ancona, 60126, Italy

  • Local Institution - 0016

    West Hollywood, California, 90069, United States

  • Local Institution - 0017

    Bakersfield, California, 93309, United States

  • Local Institution - 0018

    Dallas, Texas, 75231, United States

  • Local Institution - 0019

    Denver, Colorado, 80218, United States

  • Local Institution - 0020

    Tucson, Arizona, 85715, United States

  • Local Institution - 0021

    Jacksonville, Florida, 32256, United States

  • Local Institution - 0022

    Fountain Valley, California, 92708, United States

  • Local Institution - 0023

    Antwerp, 2060, Belgium

  • Local Institution - 0026

    Warsaw, 02-106, Poland

  • Local Institution - 0027

    Chorzów, 41-500, Poland

  • Local Institution - 0028

    Bucharest, 030171, Romania

  • Local Institution - 0029

    Iași, 700483, Romania

  • Local Institution - 0030

    Toledo, 45004, Spain

  • Local Institution - 0031

    Cebeci Ankara, 06620, Turkey (Türkiye)

  • Local Institution - 0032

    London, EC1A 7BE, United Kingdom

  • Local Institution - 0034

    Heidelberg, Victoria, 3084, Australia

  • Local Institution - 0035

    Athens, 11528, Greece

  • Local Institution - 0036

    Budapest, 1097, Hungary

  • Local Institution - 0039

    Warsaw, 02-776, Poland

  • Local Institution - 0041

    Barcelona, 08036, Spain

  • Local Institution - 0042

    St. Petersburg, Florida, 33705, United States

  • Local Institution - 0043

    Ravenna, 48121, Italy

  • Local Institution - 0044

    Terni, 05100, Italy

  • Local Institution - 0045

    Kasama-shi, 3091793, Japan

  • Local Institution - 0046

    Aomori, Aomori, 0308553, Japan

  • Local Institution - 0047

    Shibukawa-shi, Gunma, 3770280, Japan

  • Local Institution - 0048

    Koto-ku, Tokyo, 135-8550, Japan

  • Local Institution - 0049

    Osaka, Osaka, 5300012, Japan

  • Local Institution - 0050

    Chiba, 260-8677, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.